Trial Profile
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs WT 2725 (Primary)
- Indications Acute myeloid leukaemia; Carcinoma; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Sunovion Pharmaceuticals
- 06 Jun 2017 Interim results (n=62) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Status changed from active, no longer recruiting to completed.
- 14 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.